Deutsche Bank AG Purchases 12,890 Shares of Vericel Co. (NASDAQ:VCEL)

Deutsche Bank AG lifted its position in shares of Vericel Co. (NASDAQ:VCEL - Free Report) by 32.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 52,999 shares of the biotechnology company's stock after acquiring an additional 12,890 shares during the quarter. Deutsche Bank AG owned approximately 0.11% of Vericel worth $2,910,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in VCEL. Meeder Asset Management Inc. lifted its position in shares of Vericel by 8.4% during the fourth quarter. Meeder Asset Management Inc. now owns 2,357 shares of the biotechnology company's stock worth $129,000 after acquiring an additional 183 shares in the last quarter. Atria Investments Inc raised its stake in shares of Vericel by 2.4% during the 4th quarter. Atria Investments Inc now owns 7,952 shares of the biotechnology company's stock valued at $437,000 after purchasing an additional 184 shares during the period. Captrust Financial Advisors raised its stake in shares of Vericel by 3.4% during the 4th quarter. Captrust Financial Advisors now owns 6,111 shares of the biotechnology company's stock valued at $336,000 after purchasing an additional 199 shares during the period. Louisiana State Employees Retirement System lifted its holdings in Vericel by 0.8% during the 4th quarter. Louisiana State Employees Retirement System now owns 23,900 shares of the biotechnology company's stock worth $1,312,000 after purchasing an additional 200 shares in the last quarter. Finally, Avantax Advisory Services Inc. boosted its stake in Vericel by 1.7% in the 4th quarter. Avantax Advisory Services Inc. now owns 13,803 shares of the biotechnology company's stock worth $758,000 after purchasing an additional 234 shares during the period.

Vericel Stock Performance

Vericel stock traded up $1.15 during mid-day trading on Tuesday, hitting $42.07. 599,543 shares of the company traded hands, compared to its average volume of 410,131. Vericel Co. has a one year low of $37.39 and a one year high of $63.00. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of 701.28 and a beta of 1.31. The stock has a fifty day moving average price of $41.86 and a 200-day moving average price of $50.88.

Vericel (NASDAQ:VCEL - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.14). Vericel had a return on equity of 1.48% and a net margin of 1.56%. The company had revenue of $52.60 million for the quarter, compared to the consensus estimate of $53.86 million. During the same period in the prior year, the firm posted ($0.08) earnings per share. The business's revenue was up 2.6% on a year-over-year basis. Sell-side analysts predict that Vericel Co. will post 0.14 EPS for the current year.

Insider Buying and Selling at Vericel

In related news, CEO Dominick Colangelo sold 24,850 shares of the stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $41.89, for a total transaction of $1,040,966.50. Following the transaction, the chief executive officer now owns 260,354 shares of the company's stock, valued at approximately $10,906,229.06. This trade represents a 8.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 5.20% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on VCEL shares. Wall Street Zen cut Vericel from a "hold" rating to a "sell" rating in a research report on Monday, May 12th. HC Wainwright reaffirmed a "buy" rating and set a $60.00 target price on shares of Vericel in a report on Friday, February 28th. Canaccord Genuity Group increased their target price on shares of Vericel from $64.00 to $67.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. Truist Financial reduced their price target on shares of Vericel from $61.00 to $51.00 and set a "buy" rating for the company in a research report on Friday, April 11th. Finally, Stephens reaffirmed an "overweight" rating and issued a $67.00 price target on shares of Vericel in a report on Thursday, May 22nd. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, Vericel has a consensus rating of "Moderate Buy" and a consensus target price of $61.14.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.